Kenneth A Feder1, Noa Krawczyk2, Ramin Mojtabai2, Rosa M Crum3, Gregory Kirk3, Shruti H Mehta3. 1. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Hampton House 782, 624 N Broadway, Baltimore, MD 21205, United States of America. Electronic address: Kfeder1@jhu.edu. 2. Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, 624 North Broadway, Baltimore, MD 21205, United States of America. 3. Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, 615 North Wolfe Street, Baltimore, MD 21205, United States of America.
Abstract
OBJECTIVE: Understand how insurance impacts access to services among people who have injected drugs. METHODS: 1748 adults who have injected drugs were assessed at twice-annual study visits between 2006 and 2017 (18,869 visits). Use of specialty substance use treatment, receipt of buprenorphine, and having a regular source of medical care were assessed for association with concurrent insurance coverage. Random intercept logistic regression was used to adjust for potential confounders. RESULTS: When participants acquired insurance, they were more likely to report specialty substance use treatment (aOR 2.0, 95% CI 1.6 to 2.5), a buprenorphine prescription (aOR 3.3, 95% CI 2.0 to 5.5), and a regular source of medical care (aOR 6.3, 95% CI 5.1 to 7.8). CONCLUSION: Insurance is associated with increased use of three important services for individuals who inject drugs. IMPLICATIONS: Expanding insurance may facilitate access to substance use treatment and other needed health services.
OBJECTIVE: Understand how insurance impacts access to services among people who have injected drugs. METHODS: 1748 adults who have injected drugs were assessed at twice-annual study visits between 2006 and 2017 (18,869 visits). Use of specialty substance use treatment, receipt of buprenorphine, and having a regular source of medical care were assessed for association with concurrent insurance coverage. Random intercept logistic regression was used to adjust for potential confounders. RESULTS: When participants acquired insurance, they were more likely to report specialty substance use treatment (aOR 2.0, 95% CI 1.6 to 2.5), a buprenorphine prescription (aOR 3.3, 95% CI 2.0 to 5.5), and a regular source of medical care (aOR 6.3, 95% CI 5.1 to 7.8). CONCLUSION: Insurance is associated with increased use of three important services for individuals who inject drugs. IMPLICATIONS: Expanding insurance may facilitate access to substance use treatment and other needed health services.
Authors: Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander Journal: Annu Rev Public Health Date: 2015-01-12 Impact factor: 21.981
Authors: Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; Mary C Dufour; Wilson Compton; Roger P Pickering; Kenneth Kaplan Journal: Arch Gen Psychiatry Date: 2004-08
Authors: Alexander Y Walley; Julie K Alperen; Debbie M Cheng; Michael Botticelli; Carolyn Castro-Donlan; Jeffrey H Samet; Daniel P Alford Journal: J Gen Intern Med Date: 2008-09 Impact factor: 5.128
Authors: Bradley D Stein; Adam J Gordon; Andrew W Dick; Rachel M Burns; Rosalie Liccardo Pacula; Carrie M Farmer; Douglas L Leslie; Mark Sorbero Journal: J Subst Abuse Treat Date: 2014-08-02
Authors: Katherine Baicker; Sarah L Taubman; Heidi L Allen; Mira Bernstein; Jonathan H Gruber; Joseph P Newhouse; Eric C Schneider; Bill J Wright; Alan M Zaslavsky; Amy N Finkelstein Journal: N Engl J Med Date: 2013-05-02 Impact factor: 91.245
Authors: Kayla N Tormohlen; Noa Krawczyk; Kenneth A Feder; Kira E Riehm; Rosa M Crum; Ramin Mojtabai Journal: Health Serv Res Date: 2019-12-29 Impact factor: 3.402
Authors: Katherine Mackey; Stephanie Veazie; Johanna Anderson; Donald Bourne; Kim Peterson Journal: J Gen Intern Med Date: 2020-11-03 Impact factor: 5.128